These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 32235561)

  • 1. Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy.
    Aversa I; Malanga D; Fiume G; Palmieri C
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses.
    Kidman J; Principe N; Watson M; Lassmann T; Holt RA; Nowak AK; Lesterhuis WJ; Lake RA; Chee J
    Front Immunol; 2020; 11():587014. PubMed ID: 33163002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymic Function and T-Cell Receptor Repertoire Diversity: Implications for Patient Response to Checkpoint Blockade Immunotherapy.
    Cardinale A; De Luca CD; Locatelli F; Velardi E
    Front Immunol; 2021; 12():752042. PubMed ID: 34899700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-Intrinsic Barriers of T Cell-Based Immunotherapy.
    Ghoneim HE; Zamora AE; Thomas PG; Youngblood BA
    Trends Mol Med; 2016 Dec; 22(12):1000-1011. PubMed ID: 27825667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of TCR repertoire patterns linked with anti-cancer immunotherapy.
    Vandoren R; Gielis S; Laukens K; Meysman P
    Methods Cell Biol; 2024; 183():115-142. PubMed ID: 38548409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer.
    Looney TJ; Topacio-Hall D; Lowman G; Conroy J; Morrison C; Oh D; Fong L; Zhang L
    Front Immunol; 2019; 10():2985. PubMed ID: 31993050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing TCR for cancer immunotherapy.
    Voss RH; Kuball J; Theobald M
    Methods Mol Med; 2005; 109():229-56. PubMed ID: 15585925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer.
    Liu YY; Yang QF; Yang JS; Cao RB; Liang JY; Liu YT; Zeng YL; Chen S; Xia XF; Zhang K; Liu L
    Int J Cancer; 2019 Sep; 145(5):1423-1431. PubMed ID: 30664810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.
    Wennhold K; Thelen M; Schlößer HA; Haustein N; Reuter S; Garcia-Marquez M; Lechner A; Kobold S; Rataj F; Utermöhlen O; Chakupurakal G; Theurich S; Hallek M; Abken H; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
    Cancer Immunol Res; 2017 Sep; 5(9):730-743. PubMed ID: 28778961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell receptor affinity in the age of cancer immunotherapy.
    Hoffmann MM; Slansky JE
    Mol Carcinog; 2020 Jul; 59(7):862-870. PubMed ID: 32386086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of T cell receptor (TCR) repertoire analysis for the advancement of cancer immunotherapy.
    Joshi K; Milighetti M; Chain BM
    Curr Opin Immunol; 2022 Feb; 74():1-8. PubMed ID: 34454284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.
    Rudqvist NP; Pilones KA; Lhuillier C; Wennerberg E; Sidhom JW; Emerson RO; Robins HS; Schneck J; Formenti SC; Demaria S
    Cancer Immunol Res; 2018 Feb; 6(2):139-150. PubMed ID: 29180535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell repertoire diversity: friend or foe for protective antitumor response?
    Porciello N; Franzese O; D'Ambrosio L; Palermo B; Nisticò P
    J Exp Clin Cancer Res; 2022 Dec; 41(1):356. PubMed ID: 36550555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.
    Schrama D; Ritter C; Becker JC
    Semin Immunopathol; 2017 Apr; 39(3):255-268. PubMed ID: 28074285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune repertoire: A potential biomarker and therapeutic for hepatocellular carcinoma.
    Han Y; Li H; Guan Y; Huang J
    Cancer Lett; 2016 Sep; 379(2):206-12. PubMed ID: 26188280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ushering in Integrated T Cell Repertoire Profiling in Cancer.
    Jiang N; Schonnesen AA; Ma KY
    Trends Cancer; 2019 Feb; 5(2):85-94. PubMed ID: 30755308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell receptor repertoire analysis for the diagnosis and treatment of solid tumor: A methodology and clinical applications.
    Li N; Yuan J; Tian W; Meng L; Liu Y
    Cancer Commun (Lond); 2020 Oct; 40(10):473-483. PubMed ID: 32677768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data.
    Zhang L; Cham J; Paciorek A; Trager J; Sheikh N; Fong L
    BMC Bioinformatics; 2017 Feb; 18(1):129. PubMed ID: 28241742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New checkpoints in cancer immunotherapy.
    Ni L; Dong C
    Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.